BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34718055)

  • 1. Pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis.
    Zhou P; Zhang Y; Luo S; Zhang S
    Radiother Oncol; 2021 Dec; 165():103-118. PubMed ID: 34718055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
    Huang J; Gu F; Ji T; Zhao J; Li G
    Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
    Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
    Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
    Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review.
    Corbeau A; Kuipers SC; de Boer SM; Horeweg N; Hoogeman MS; Godart J; Nout RA
    Radiother Oncol; 2021 Nov; 164():128-137. PubMed ID: 34560187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Rapid arc-based Radiation Therapy on Dosimetric Parameters in Cervical Cancer Patients with and without Bone Marrow Sparing.
    Aggarwal R; Sood S; Singh M; Singh K; Sood D; Mupasana V; Palanisamy M
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2407-2413. PubMed ID: 35901348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
    Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
    Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
    Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
    Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
    Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dosimetric analysis of tomotherapy based intensity modulated radiation therapy with and without bone marrow sparing in gynecologic malignancies.
    Platta CS; Bayliss A; McHaffie D; Tome WA; Straub MR; Bradley KA
    Technol Cancer Res Treat; 2013 Feb; 12(1):19-29. PubMed ID: 22974331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating
    Franco P; Fiandra C; Arcadipane F; Trino E; Giglioli FR; Ragona R; Ricardi U
    BMC Cancer; 2017 Nov; 17(1):710. PubMed ID: 29096619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study.
    Li W; Ma L; Li F; Li K; Zhang Y; Ren H; Bao X; Guo Y; Guo Y; Wang M; Li D; Duan Y; Ma X; Wang Z; Wang Y; Yin R
    Radiat Oncol; 2024 Apr; 19(1):46. PubMed ID: 38594678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
    Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
    Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical study of acute toxicity of pelvic bone marrow-sparing intensity-modulated radiotherapy for cervical cancer.
    Sun S; Chen Z; Li P; Wu J; Zhu B; Zhang X; Wu C; Lin R; Zhou Y; Chen W
    Ginekol Pol; 2023; 94(2):101-106. PubMed ID: 35156692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
    Mell LK; Tiryaki H; Ahn KH; Mundt AJ; Roeske JC; Aydogan B
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1504-10. PubMed ID: 18640499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
    Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
    Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.
    Sini C; Fiorino C; Perna L; Noris Chiorda B; Deantoni CL; Bianchi M; Sacco V; Briganti A; Montorsi F; Calandrino R; Di Muzio N; Cozzarini C
    Radiother Oncol; 2016 Jan; 118(1):79-84. PubMed ID: 26702990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
    Rose BS; Aydogan B; Liang Y; Yeginer M; Hasselle MD; Dandekar V; Bafana R; Yashar CM; Mundt AJ; Roeske JC; Mell LK
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):800-7. PubMed ID: 20400238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
    Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
    Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
    Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
    Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.